An interventional study of Triamcinolone acetonide with lidocaine and Open surgical release of first dorsal extensor compartment in DeQuervain's Tenosynovitis, sponsored by Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This quasi-experimental study compared pain outcomes following local corticosteroid injection (CSI) versus open surgical release in 100 patients with clinically confirmed De Quervain tenosynovitis unresponsive to conservative management. Patients were allocated to treatment based on clinician judgment and patient preference. Pain was assessed using the Visual Analog Scale (VAS) at baseline, one month, and six months post-intervention. The study was conducted at a single tertiary care centre in Rawalpindi, Pakistan between March 2023 and April 2025.
De Quervain tenosynovitis is a stenosing tendinopathy of the first dorsal extensor compartment of the wrist, causing radial-sided wrist pain. One hundred patients were enrolled and allocated to either corticosteroid injection (CSI; n=49) or open surgical release (n=51). The CSI protocol consisted of triamcinolone acetonide (40mg/mL, 1mL) combined with 1% lidocaine (1mL) injected into the first dorsal compartment under aseptic conditions. Surgical release involved longitudinal decompression of the fibro-osseous sheath overlying the APL and EPB tendons. The primary outcome was VAS pain score at baseline, one month, and six months. Statistical analysis included independent t-tests and linear mixed-effects modeling.
31 studies on the registry are indexed under De Quervain Disease; 8 are open to participants now.
This study's enrollment of 100 is above the median of 49 across 27 interventional studies indexed under De Quervain Disease.
Browse De Quervain Disease studies →Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Single injection of triamcinolone acetonide (40mg/mL, 1mL) combined with 1% lidocaine (1mL) administered into the first dorsal extensor compartment under aseptic conditions without ultrasound guidance.
Drug: Triamcinolone acetonide with lidocaine
Open decompression of the first dorsal compartment through a longitudinal incision over the radial styloid, with release of the fibro-osseous sheath overlying the APL and EPB tendons, closed with non-absorbable sutures.
Procedure: Open surgical release of first dorsal extensor compartment
Drug pages: Triamcinolone AcetonideStudies of Triamcinolone AcetonideTriamcinolone Acetonide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LidocaineStudies of LidocaineLidocaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Triamcinolone acetonide 40mg/mL (1mL) + 1% lidocaine (1mL) - single injection
Longitudinal decompression of the fibro-osseous sheath overlying APL and EPB tendons
Pain intensity - Visual Analog Scale (VAS)
Pain scored on a 0-10 VAS scale where 0 = no pain and 10 = worst imaginable pain, assessed by a blinded assessor
Time frame: Time Frame: Baseline, 1 month, and 6 months post-intervention
Adverse events
Any complications or adverse events recorded in either treatment group
Time frame: Throughout 6-month follow-up period
Plan to share: No — Individual participant data are not publicly available due to institutional privacy policies but are available from the corresponding author upon reasonable request.
No publications or documents are linked to this record.
Ran from Mar 2023 to primary completion in Apr 2025, 25 months.
Of 16 interventional studies with no phase under De Quervain Disease, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 28. This study's 25 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Triamcinolone Acetonide · Lidocaine
Rawalpindi Teaching Hospital, District Headquarter Hospital, Rawalpindi